Abstract PD8-08: Pyrotinib in Combination with Trastuzumab and Docetaxel As Neoadjuvant Treatment for HER2-positive Early or Locally Advanced Breast Cancer (PHEDRA): A Randomized, Double-Blind, Multicenter, Phase 3 Study